Dr Le Chevalier speaks about the work carried out at the Gustave-Roussy Institute and the difficulties faced when treating lung cancer. In order to address some of these issues a new institute of thoracic oncology is being established to combine the expertise of both Gustave-Roussy Institute and Centre Chirgical Marie Lannelongue. Dr Le Chevalier discusses research into two promising new drugs currently part of a phase III study; one associated with the EGFR pathway and the other an angiogenesis inhibitor.